Abstract LB-233: Immune-related efficacy data of the phase 1-2 study of an with fourfold gene-modified allogeneic tumor cell based vaccine in patients with advanced renal cell carcinoma

Ekaterina Weith(Mologen (Germany)), Burghardt Wittig, Marina Tschaika(Bristol-Myers Squibb (United States)), Ingo GH Schmidt-Wolf(University Hospital Bonn), Manuel Schmidt(Mologen (Germany)), Viktor Gruenwald(Medizinische Hochschule Hannover), Steffen Weikert(St. Hedwig-Krankenhaus), Matthias Schroff(Mologen (Germany)), Kerstin Kapp(Mologen (Germany)), Stefan Hauser(German Center for Neurodegenerative Diseases)
Cancer Research
April 1, 2012
10.1158/1538-7445.am2012-lb-233
Cited by 0

Related Papers

The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2020|421
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2017|380
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
|The Lancet Oncology|2016|218
The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
|European Journal of Cancer|2010|187